Joan-Lluis Vives Corrons

Prof. Dr. Joan-Lluis Vives Corrons

Red Blood Cell and Hematopoietic Disorders Research Lab., Institute for Leukaemia Research Josep Carreras, Ctra de Can Ruti, Camí de les Escoles s/n. 08916-Badalona (Barcelona), Spain
orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2017 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
ELE. Llaudet‐Planas
E. Llaudet‐Planas
JCJoan-Lluis Vives Corrons
Joan-Lluis Vives Corrons
VRV. Rizzuto
V. Rizzuto
PGP. Gómez‐Ramírez
P. Gómez‐Ramírez
JSJulián Sevilla
Julián Sevilla
MMM. M. Mañú‐Pereira
M. M. Mañú‐Pereira

3 August 2021 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
JCJoan-Lluis Vives Corrons
Joan-Lluis Vives Corrons
LCL. Berga Casafont
L. Berga Casafont
EFE. Feliu Frasnedo
E. Feliu Frasnedo

19 October 2020 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
JCJoan-Lluis Vives Corrons
Joan-Lluis Vives Corrons
EKElena Krishnevskaya
Elena Krishnevskaya
IRInes Hernandez Rodriguez
Ines Hernandez Rodriguez
AAAgueda Ancochea
Agueda Ancochea

16 February 2023 in Thalassemia Reports
Verified
Journal Article
Open access
PDF file
EKElena Krishnevskaya
Elena Krishnevskaya
MMMarta Molero
Marta Molero
ÁAÁgueda Ancochea
Águeda Ancochea
IHInes Hernandez-Rodriguez
Ines Hernandez-Rodriguez
JCJoan-Lluis Vives Corrons
Joan-Lluis Vives Corrons
Next-generation ektacytometry provided by the osmoscan module of the Laser Optical Rotational Red Cell Analyser (LoRRca) MaxSis is, so far, one of the best complementary diagnostic tools for congenital rare anaemias due to red blood cell defects. Osmotic gradient ektacytometry (OGE) is currently considered the gold standard for the diagnosis of red cell membrane disorders, especially hereditary spherocytosis (HS). Impairment of red cell deformability, leading to a decrease in red cell survival rate, is the common trait of hereditary haemolytic anaemias; in general, it is the consequence of an abnormal cell shape, increased rigidity or dehydration. Up to now, the next-generation ektacytometry has been mainly used for the differential diagnosis of red blood cell membranopathies, but experience with structural hemoglobinopathies and thalassemia is still scarce. However, recently, many new forms of therapy are being developed for the treatment of hemoglobinopathies, particularly sickle-cell disease and β-thalassemia; clinical interest in ektacytometry is increasing and should be further explored. Here, we have evaluated the OGE profiles provided by the osmoscan module of the LoRRca ektacytometer in 96 patients with different hemoglobinopathies, both structural and thalassemia, with the aim of analysing their usefulness for the early diagnosis of these disorders either individually or in co-inheritance with other hereditary RBC defects. In addition, this study aims to improve our knowledge of the contribution of red cell deformability, osmotic fragility and intracellular viscosity to the physiopathology of haemolysis, especially when these disorders are a cause of rare anaemia. From this study, we conclude that the osmoscan profile provides complementary information on red cell deformability and hydration homeostasis that may contribute to the better understanding of the physiopathology of decreased red cell survival and hemolysis which is present in some patients.

11 May 2020
Verified
Journal Article
Open access
JCJoan-Lluis Vives Corrons
Joan-Lluis Vives Corrons
VSVincenzo De Sanctis
Vincenzo De Sanctis
For rare haematological diseases (RHD), the first question to be answered is if patients with benign red blood cell (RBC) defects like haemoglobinopathies, membranopathies and enzymopathies are more vulnerable to COVID-19 infection. Up to now, there is no yet literature on the subject, but, like in general population, the presence of comorbidities such as diabetes, heart disease, pulmonary hypertension, reduced kidney and/or liver function, worsen the effects of the infection. Splenectomy may be an additional risk factor. (www.actabiomedica.it)

10 November 2020
Verified
Journal Article
Open access
DCDuran Canatan
Duran Canatan
JCJoan-Lluis Vives Corrons
Joan-Lluis Vives Corrons
VSVincenzo De Sanctis
Vincenzo De Sanctis
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people with COVID-19 have a mild to moderate respiratory illness; others experience severe illness, such as COVID-19 pneumonia. The first and most accessible diagnostic information is from symptoms and signs from clinical examination. Infected patients present with a variety of manifestations. Formal diagnosis requires laboratory analysis of nose and throat samples, or imaging tests like CT scans. Emerging data suggest that coronavirus disease 2019 (COVID-19) has extrapulmonary manifestations. Sometimes these extra-respiratory manifestations may be the initial or only symptom of COVID-19, prior to fever or respiratory manifestations. In summary, our concise review shows that there is a wide range of symptoms that can be presented by COVID-19 patients. Extra-respiratory manifestations of SARS-CoV-2 infection have recently been observed in the rapidly increasing number of COVID-19 cases. Considering the broad spectrum of clinical manifestations and the increasing worldwide burden of the disease, there is an urgent need to rapidly scale up the diagnostic capacity to detect COVID-19 and its complications.